Institute of Molecular Biology and Pathology CNR, Department of Molecular Medicine, University Sapienza, Rome, Italy.
BMC Mol Biol. 2013 Jan 30;14:3. doi: 10.1186/1471-2199-14-3.
Duchenne muscular dystrophy (DMD) is the most common X-linked muscle degenerative disease and it is due to the absence of the cytoskeletal protein dystrophin. Currently there is no effective treatment for DMD. Among the different strategies for achieving a functional recovery of the dystrophic muscle, the upregulation of the dystrophin-related gene utrophin is becoming more and more feasible.
We have previously shown that the zinc finger-based artificial transcriptional factor "Jazz" corrects the dystrophic pathology in mdx mice by upregulating utrophin gene expression. Here we describe a novel artificial transcription factor, named "UtroUp", engineered to further improve the DNA-binding specificity. UtroUp has been designed to recognise an extended DNA target sequence on both the human and mouse utrophin gene promoters. The UtroUp DNA-binding domain contains six zinc finger motifs in tandem, which is able to recognise an 18-base-pair DNA target sequence that statistically is present only once in the human genome. To achieve a higher transcriptional activation, we coupled the UtroUp DNA-binding domain with the innovative transcriptional activation domain, which was derived from the multivalent adaptor protein Che-1/AATF. We show that the artificial transcription factor UtroUp, due to its six zinc finger tandem motif, possesses a low dissociation constant that is consistent with a strong affinity/specificity toward its DNA-binding site. When expressed in mammalian cell lines, UtroUp promotes utrophin transcription and efficiently accesses active chromatin promoting accumulation of the acetylated form of histone H3 in the utrophin promoter locus.
This novel artificial molecule may represent an improved platform for the development of future applications in DMD treatment.
杜氏肌营养不良症(DMD)是最常见的 X 连锁肌肉退行性疾病,其病因是细胞骨架蛋白肌营养不良蛋白的缺失。目前,DMD 尚无有效的治疗方法。在实现抗肌营养不良蛋白基因 utrophin 功能恢复的各种策略中,上调 utrophin 基因表达变得越来越可行。
我们之前已经表明,基于锌指的人工转录因子“Jazz”通过上调 utrophin 基因表达来纠正 mdx 小鼠的肌肉营养不良病理。在这里,我们描述了一种新型的人工转录因子,命名为“UtroUp”,旨在进一步提高 DNA 结合特异性。UtroUp 被设计用来识别人类和小鼠 utrophin 基因启动子上的扩展 DNA 靶序列。UtroUp 的 DNA 结合结构域包含串联的六个锌指基序,能够识别统计上仅在人类基因组中存在一次的 18 碱基对 DNA 靶序列。为了实现更高的转录激活,我们将 UtroUp DNA 结合结构域与创新的转录激活结构域结合,该结构域源自多价接头蛋白 Che-1/AATF。我们表明,由于其六个锌指串联基序,人工转录因子 UtroUp 具有较低的解离常数,这与其 DNA 结合位点的强亲和力/特异性一致。当在哺乳动物细胞系中表达时,UtroUp 促进 utrophin 转录,并有效地进入活性染色质,促进乙酰化组蛋白 H3 在 utrophin 启动子位点的积累。
这种新型人工分子可能代表着开发未来 DMD 治疗应用的改进平台。